Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children

Ella Dolan, MD, MPH; Robert Hellinga, PharmD; Matthew London, PharmD; Keenan Ryan, PharmD; and Walter Dehority, MD, MSc

OBJECTIVE Subtherapeutic vancomycin trough concentrations are common in children and may be associated with suboptimal therapeutic response. Our objective was to determine if vancomycin loading doses safely increase the frequency of target trough attainment in hospitalized children.

METHODS Patients (≥ 6 months and < 18 -years-old) who received a vancomycin loading dose between February 1, 2018, and January 30, 2019, were retrospectively enrolled. These patients were compared to a convenience cohort of patients hospitalized between January 1, 2015, and December 31, 2015, who received vancomycin without a loading dose. Target trough concentrations were defined as > 15 mg/dL for invasive infections and > 10 mg/dL for non-invasive infections.

RESULTS A total of 151 patients were enrolled, with 77 in the control arm and 74 in the loading dose arm. There was no significant difference in the frequency of comorbidities or need for intensive care unit admission between the two arms. Those receiving a vancomycin loading dose were older (mean age 9.1 vs 5.2 years, $p < 0.0001$). Patients given a loading dose achieved higher mean initial trough values (13.0 mg/dL vs 9.2 mg/dL, $p < 0.0001$), were more likely to have an initial trough at or above target (37.0% vs 10.4%, $p = 0.0001$), were more likely to reach target trough values at any point during therapy (52.1% vs 32.9%, $p = 0.0081$), and attained a target trough concentration more quickly (mean 41.1 hours vs 58.8 hours, $p = 0.0118$). There were no significant differences in the frequency of serum creatinine elevation or oliguria at the end of therapy.

CONCLUSIONS Vancomycin loading doses may improve the ability to safely obtain target trough values in hospitalized children.

ABBREVIATIONS AUC/MIC, area under the curve/minimum inhibitory concentration; ICU, intensive care unit; MRSA, Methicillin-resistant *Staphylococcus aureus*

KEYWORDS pediatric; pharmacokinetics; target attainment; therapeutic drug monitoring; vancomycin

J Pediatr Pharmacol Ther 2020;25(5):423–430

DOI: 10.5863/1551-6776-25.5.423

Introduction

Vancomycin is a large glycopeptide antibiotic that directs its activity against the bacterial cell wall.¹ It is commonly used in the treatment of serious Gram-positive infections,^{2–4} including those due to methicillin-resistant *Staphylococcus aureus* (MRSA).^{1,5} Despite having been in clinical use for more than 60 years, it still retains potent activity against most strains of *S aureus* and other Gram-positive pathogens⁶ and is considered a first-line agent for use in hospitalized children infected with these organisms.⁷ Clinical and animal data^{2,8–10} suggest that vancomycin killing is not concentration dependent, and pharmacokinetic/pharmacodynamic data^{2,3,11,12} suggest that, as a result, the area under the curve/minimum inhibitory concentration (AUC/MIC) may be the best predictor of clinical response, particularly for lung infections. The data for this parameter are more robust in adults, but it has also demonstrated utility in children.⁷ However, it is often logistically difficult to

calculate this value given the multiple blood specimens required (particularly in children, in whom repeated venipunctures are often challenging) and the need for an accurate MIC from an organism in a timely fashion. In addition, the lack of data associating AUC/MIC to outcomes in children and a lack of formal recommendations for how to use this parameter in children conspire to make adoption of this approach in pediatrics difficult.⁴ As a result, serum trough minimum concentrations of vancomycin are often used as a surrogate for AUC/MIC to gauge the appropriateness of dosing.^{2,13} In adults the trough concentrations are ideally 10 to 15 mg/dL for skin and soft tissue infections and 15 to 20 mg/dL for more severe infections.

Despite standard dosing based upon accepted references,¹⁴ initial vancomycin trough values in children are often subtherapeutic or below target goals.¹⁵ Orr et al¹⁵ reported that 79.2% of appropriately dosed pediatric oncology patients had subtherapeutic initial vancomycin trough concentrations, while Hsu et al¹⁶ detailed

a cohort of children with MRSA bacteremia, 73.0% of whom had a median vancomycin trough concentration of <10 mg/dL. Hoang et al¹⁷ described a cohort of 188 children, 61.0% of whom failed to achieve target trough concentrations following vancomycin dosing, while Durham et al¹⁸ reported that only 6.8% of 74 children receiving vancomycin at 60 mg/kg/day divided every 6 hours achieved a trough concentration of 15 to 20 mg/dL. Randolph et al¹⁹ also reported that among 170 children receiving vancomycin for an MRSA coinfection following influenza disease, 78.0% failed to achieve an initial trough value of 10 mg/dL. More concerning are recent reports associating subtherapeutic vancomycin trough concentrations with poor clinical outcomes. Hsu et al¹⁶ found that a longer duration of MRSA bacteremia was associated with a vancomycin trough concentration of <10 mg/dL within the first 72 hours of therapy. Children with vancomycin trough values of <10 mg/dL in this cohort were 3 times as likely to have MRSA bacteremia lasting more than 3 days than were those children with trough concentrations of >10 mg/dL.¹⁶ Yoo et al²⁰ documented similar findings in a study of 46 children with MRSA bacteremia, in which those children with vancomycin trough values of <10 mg/dL were significantly more likely to experience a bacteremia lasting greater than 2 days (although this finding did not remain significant in multivariable analysis). Hamdy et al²¹ documented that every 1-day increase in MRSA bacteremia duration results in a 50.0% increase in the odds that a complication will appear, which argues for a need for rapid clearance of bacteremia.

These findings suggest a need to further investigate strategies to more consistently and rapidly achieve target vancomycin concentrations in children. Recently, studies^{3,22–24} have demonstrated that vancomycin loading doses may improve the likelihood of attaining early target trough concentrations in adult patients. However, there are limited data regarding the safety and efficacy of this approach in children. To our knowledge, only one study has investigated the use of vancomycin loading doses in pediatric patients. Demirjian et al²⁵ did not demonstrate any benefit with loading doses in a 2013 randomized controlled trial in children. However, the study did not appear powered to address the question, with only 19 children enrolled in the loading dose group (46 overall), with the primary outcome an 8-hour serum concentration, prior to steady-state attainment. An abstract²⁶ presented in 2014 reported a median trough concentration of 10.9 mg/dL in an uncontrolled study of vancomycin loading doses in 19 children aged 3 months to 18 years. However, this study was limited by a small sample size and lack of a control group.

Given the apparent success of vancomycin loading doses in adult medicine, this practice should be evaluated more thoroughly for use in children. To this end, we conducted a retrospective study of hospitalized children receiving vancomycin to investigate the

relationship between receipt of a loading dose and the frequency of safely attaining the initial target trough concentrations.

Materials and Methods

We implemented a pediatric vancomycin loading dose protocol at the University of New Mexico Hospital on February 1, 2018. The recommended pediatric loading dose of 20 to 25 mg/kg/dose was determined based on extrapolation from adult loading dose data and preliminary data on the frequency of subtherapeutic vancomycin trough values (below target concentrations) requiring dose corrections to the 20 to 25 mg/kg dose range in children at our institution.^{3,14,24} While the protocol recommended use of a loading dose, administration of a loading dose was ultimately at the discretion of the treating clinicians.

We conducted a retrospective cohort study of children hospitalized in the first year following implementation of these new vancomycin loading dose guidelines (February 1, 2018, to January 31, 2019), with comparison to a convenience cohort of children receiving vancomycin without a loading dose (January 1, 2015, to December 31, 2015).

Eligible subjects were hospitalized at our institution during the relevant time periods and were between the ages of 6 months and 18 years. Those under 6 months of age were excluded, as glomerular filtration rate reaches adult values by this age, thus providing a more comparable cohort.²⁷ Subjects also had to have received vancomycin for at least 24 hours followed by an appropriately collected trough. Appropriate troughs were defined as being collected within 1 hour of the next scheduled dose and were obtained at presumed steady state (within 1 hour of the 24-hour dose; e.g., within 1 hour of the third dose for every 8-hour dosing; within 1 hour of the fourth dose for each 6-hour dosing) per Infectious Disease Society of America guidelines.^{3,14} Our hospital has no defined protocol for monitoring vancomycin trough values after the first 24 hours. Once a target trough value is obtained, routine monitoring of trough concentrations would occur every 5 to 7 days, unless unstable renal function was a concern, in which case more frequent trough concentrations would be obtained on a case-by-case basis. If given, the loading dose was counted as the first dose administered.

Data for eligible subjects were collected from electronic medical records. Abstracted data included demographic information, dosing data (dose, timing in relation to trough, duration of therapy, number of dosing changes), indication for therapy, culture results (if obtained), medical comorbidities, need for intensive care unit admission, duration of hospital stay, and all trough values obtained. If available, serum creatinine and urine output values (mL/kg/hr) within 24 hours of the initial trough value and within 24 hours of vancomycin discontinuation were collected and compared to assess

for nephrotoxicity. Creatinine concentrations above age-appropriate values were considered abnormal. Although age-specific values for normal urine output are not well defined, we considered oliguria as a urine output of <1 mL/kg/hr in children between 6 months and 1 year of age and of <0.5 mL/kg/hr in older children.^{28–30} An appropriate maintenance dose was defined as 40 to 60 mg/kg/day (± 5 mg/kg/day) for non-invasive infections (e.g., skin/soft tissue infections without systemic involvement, lower urinary tract infections) and 60 mg/kg/day (± 5 mg/kg/day) for invasive infections (e.g., meningitis, bacteremia, osteoarticular infections), per institutional guidelines.¹⁴ Target trough concentrations were defined as 10 to 15 mg/dL for non-invasive infections and 15 to 20 mg/dL for invasive infections, as previously defined.^{3,14,25,31} Although ambiguity exists with regard to the clinical significance of specific trough values, as well as the relationship between trough values and the AUC/MIC, given the frequent reliance on national guidelines and references that advocate use of a vancomycin trough in the 15 to 20 mg/dL range for serious infections, we used this as our reference point for a therapeutic or target trough value.^{3,14,31,32} Data were entered into a REDCap database,³³ followed by extraction to Stata (version 11.2, 2012) for statistical analysis.

For power calculations, we estimated a 20.8% target trough attainment without a loading dose from previously published work in children,¹⁵ with an estimated 50.0% target trough attainment with the use of loading doses (based upon previous adult and pediatric data).^{22,26} Using an alpha of 0.05 and 90% desired power, we estimated we would require 108 subjects (54 in each group) in order to detect a statistically significant difference in our primary outcome (initial target trough attainment), should one exist.

Basic descriptive statistics (e.g., calculation of frequencies) were used for characterization of the cohort. A chi-square test was used to assess for significant differences between categorical variables, while comparison of mean values was conducted with Welch's unequal variances *t*-test. To analyze for the effect of age as a confounder on the attainment of a target trough, a logistic regression model was created with attainment of a target trough as the dependent variable, and a likelihood ratio test was conducted to assess for significant differences with and without the variable of interest (Wald *t*-test). Statistical significance was defined as a *p* value of <0.05 .

Results

In the 2015 standard dosing cohort, 312 subjects were identified as having received at least one dose of vancomycin (with 77 eligible), while 307 subjects were identified in the loading dose period as having received at least one dose of vancomycin (with 74 eligible) (Figure A and B). Overall, 151 subjects were enrolled.

Subjects receiving a loading dose were older (mean

age 9.1 vs 5.2 years, $p < 0.0001$), more likely to be female (59.5% vs 42.9%, $p = 0.0208$), and demonstrated higher body weights (35.5 vs 19.0 kg, $p < 0.0001$) than did those not receiving loading doses (Table 1). Of note, subjects excluded from the loading dose cohort for not receiving a loading dose were also significantly older than those in the control group (mean age 9.9 vs 5.2 years, $p = 0.005$, median 10.2 years, IQR 5.0 to 6.9 years). There were no significant differences between the groups in terms of race, ethnicity, the frequency of MRSA isolation, the presence of medical comorbidities, or the frequency of intensive care unit admission (Table 1). The most common medical comorbidities were oncologic disorders ($n = 22$, or 14.6% overall) followed by short bowel syndrome ($n = 17$, or 11.3% overall), while the most common organism isolated was *S aureus* ($n = 26$, 42.6% of all organisms cultured), with blood the most common site of isolation ($n = 37$ and 38.9% of all cultures).

Each group received similar initial maintenance doses of vancomycin (mean dose 57.5 vs 55.7 mg/kg/day, $p = 0.736$). This initial dose was deemed appropriate based upon the indication for treatment in 78.1% of loading dose subjects and 81.7% of conventional dosing subjects ($p = 0.4215$). The mean loading dose used was 23.4 mg/kg (median 24.4 mg/kg; IQR 20.0 mg/kg to 25.0 mg/kg). Troughs were collected a mean of 0.37 hours prior to the next dose (median 0.3 hours; IQR 0.1 to 0.6 hours for the cohort as a whole). There was no difference between the timing of trough collection between groups (0.36 vs 0.36 hours, $p = 0.490$). There were no significant differences in the frequency of dosing, indication for vancomycin treatment, or organism isolated between groups.

Subjects receiving a loading dose demonstrated higher mean initial trough values (13.0 vs 9.2 mg/dL, $p < 0.0001$) and were more likely to achieve a target initial trough (37.0% vs 10.4%, $p = 0.0001$) (Table 2). A significantly higher percentage of subjects who received a loading dose attained an initial trough of >10 mg/dL (64.4% vs 32.9%, $p < 0.0001$) and were more likely to have no troughs of <10 mg/dL during their hospital stay (57.5% vs 29.3%, $p = 0.0002$). Furthermore, the loading dose arm was more likely to achieve a target trough at some point during therapy (52.1% vs 32.9%, $p = 0.0081$). Subjects receiving a loading dose achieved a target trough significantly more quickly than did those not receiving a loading dose (mean 41.1 vs 58.8 hours, $p = 0.0118$). These patients also required lower maintenance doses to reach a target trough (mean dose 58.9 mg/kg vs 66.6 mg/kg, $p = 0.0672$), although this measure did not reach statistical significance. Subjects in the loading dose group were also less likely to require an increase in the initial dose of vancomycin (41.1% vs 57.1%, $p = 0.0249$).

To attempt to account for the age difference between the groups, we created a logistic regression model to

Figure. Flowchart of eligible subjects: standard dosing cohort (A); loading dose cohort (B).

control for the effect of age on our primary outcome, attainment of an initial target trough. In this model use of a loading dose was still significantly associated with the likelihood of attaining an initial target trough after controlling for age (OR = 1.14, 95% CI 1.06–1.23, $p = 0.0027$).

To account for the effect of potential dosing irregularities, we separately analyzed those subjects who only received appropriate dosing of vancomycin (for the stated indication). Differences persisted between the loading dose and the control groups for mean first trough value (13.2 vs 8.9 mg/dL, respectively, $p < 0.0001$), frequency of initial target trough attainment (36.8% vs 9.0%, $p = 0.0001$), and frequency of an initial trough of >10 mg/dL (66.7% vs 28.4%, $p < 0.0001$), although not for time to target trough attainment (42.6 vs 53.6 hours, $p = 0.0839$).

The percentage of subjects with creatinine elevation (6.1% in the non-loading dose group vs 2.7% in the loading dose group, $p = 0.4073$) or oliguria at the

end of therapy (2.4% in the non-loading dose group vs 5.5% in the loading dose group, $p = 0.3584$) was not significantly different between groups, nor was the mean number of troughs collected per subject (1.8 in the non-loading dose group vs 2.3 in the loading dose group, $p = 0.0799$) (Table 2).

Supratherapeutic troughs (>20 mg/dL) were rare and not significantly different between the non-loading dose and loading dose cohorts (3.9% vs 8.2%, respectively, $p = 0.136$). There was no significant difference in the duration of vancomycin therapy between the non-loading dose and the loading dose groups (79.9 hours vs 80.1 hours, respectively, $p = 0.4940$) or in the length of hospital stay (22.3 days vs 25.5 days, respectively, $p = 0.3292$).

Discussion

We found that hospitalized children who received a vancomycin loading dose were significantly more likely

Table 1. Demographic Characterization of the Study Cohort

Variable	Standard Dose Cohort	Loading Dose Cohort	p value
Enrolled	77	74	—
Age, yr			
Mean	5.2	9.1	<0.0001
Median	3.9	10	
IQR	1.7–7.3	3.9–13.4	
Sex, n (%)			0.0208
Male	44 (57.1)	30 (40.5)	
Female	33 (42.9)	44 (59.5)	
Race, n (%)			0.7210
White	48 (62.3)	50 (67.6)	
Native American	26 (33.8)	13 (17.6)	
Pacific Islander	1 (1.3)	1 (1.4)	
No answer	2 (2.6)	10 (13.5)	
Ethnicity, n (%)			0.5680
Hispanic	37 (48.1)	40 (54.1)	
Not Hispanic	39 (50.7)	30 (40.5)	
No answer	1 (1.3)	4 (5.4)	
Medical comorbidities	57 (74.0)	48 (64.9)	0.5940
ICU admission, n (%)	26 (33.8)	25 (34.3)	0.4755

to attain an initial target trough concentration and to do so more quickly than were those who did not, without any increase in nephrotoxicity. In addition, even those children not attaining initial target trough concentrations were significantly more likely to obtain a higher initial trough concentration, to attain a target trough at some point during therapy, and to reach a trough of at least 10 mg/dL. Therefore, given the prevalent use of trough concentrations for therapeutic drug monitoring in children receiving vancomycin, and the fact that subtherapeutic vancomycin troughs have been associated with poor outcomes in children,^{16,19} the use of pediatric vancomycin loading doses should be considered for further study.

It should be noted, however, that even with the added benefit of a loading dose, the overall attainment of initial target trough values was still not ideal in our cohort (37.0%). This may argue for higher loading doses (e.g., 25–30 mg/kg, as has been described in adults) or higher maintenance doses following a load.²² Concerns of nephrotoxicity with higher doses of vancomycin are less of a concern in children, in whom vancomycin-induced nephrotoxicity appears more common in the setting of coadministration with other nephrotoxic agents and/or in the setting of a severe underlying illness.^{34–36}

The clinical significance of vancomycin trough values is still unclear, however, with conflicting reports in the literature^{16,20,21} regarding the association between

subtherapeutic trough values and poor outcomes in children. The specific trough values required for optimal outcomes are also not well validated and likely vary by pathogen and site of infection, among other factors.^{3,16,20} Although trough concentrations are routinely used to aid in clinical decision making, there is evidence^{37,38} that trough concentrations may not reflect meaningful clinical endpoints as effectively as do other potential markers, such as the AUC/MIC. The AUC/MIC is of unproven value in children, although more study is required to better assess associations with clinical outcomes and the ability to use this parameter with only one blood measurement.^{7,32} While a consensus review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists suggests a trough of 15 to 20 mg/dL is likely necessary to reach a therapeutic AUC/MIC of >400 mg*hr/L,³ these data are based on adult populations, and this assumption may not be applicable to pediatric patients. Regen et al³² found a poor correlation between vancomycin trough concentrations and estimated AUC₂₄/MIC ratios using 2 different methodologies ($R^2 = 0.32$ and 0.22) in a study of 65 children with MRSA bacteremia. Nonetheless, the efficacy of loading doses in children should be evaluated with different pharmacokinetic and pharmacodynamic outcomes, including the AUC/MIC.

However appealing the idea of a loading dose may

Table 2. Primary Clinical Outcomes Between Non–Loading Dose and Loading Dose Groups

Variable	Standard Dose Cohort	Loading Dose Cohort	p value
Initial trough, mean, mg/dL	9.2	13.0	<0.0001
Therapeutic initial trough, %	10.4	37.0	<0.0001
No troughs <10 mg/dL, %	29.3	57.5	0.0002
Initial trough >10 mg/dL, %	32.9	64.4	<0.0001
Time to therapeutic trough, hr	58.8	41.1	0.0118
Therapeutic trough at some point during therapy, %	32.9	52.1	0.0081
Elevated EOT creatinine, %	6.1	2.7	0.4073
Oliguria at EOT, %	2.4	5.5	0.3584
Length of hospital stay, days	22.3	25.5	0.3292
Duration of vancomycin use, hr	79.9	80.1	0.4940

EOT, end of therapy

be, alternative strategies for optimizing antibiotic use in children with severe Gram-positive infections should be pursued. For example, alternative dosing strategies for vancomycin (such as the use of continuous infusions) are promising approaches. Continuous infusion of vancomycin was shown³⁹ to be superior to intermittent dosing in a randomized controlled trial of 111 infants under the age of 3 months (85% target trough attainment in the continuous infusion group vs 41% in the intermittent dosing group, $p < 0.001$) and required fewer dosage adjustments and a lower mean daily dose and demonstrated a favorable safety profile. The use of a continuous infusion of vancomycin was recently shown⁴⁰ to be an effective tool for achieving goal trough values in a retrospective study of 240 older children as well. This modality is also associated with less nephrotoxicity and a more rapid time to attainment of a therapeutic concentration in adults.^{40–42} Continuous infusions do present some limitations in children, however, as reliance on one venous access point for the infusion may impair the ability to administer other medications, particularly those that may interact with vancomycin. Continued study of alternative agents to vancomycin (e.g., those with a more favorable adverse effect profile and no need for serum drug monitoring) should be pursued. Ceftaroline, daptomycin, and dalbavancin are all relatively new agents with comparable coverage to vancomycin with expanding clinical data in children.^{43–46} Lastly, continued emphasis on antimicrobial stewardship would likely de-emphasize the need for vancomycin in many patients, thereby eliminating concerns of dosing in at least a subset of children.

Our study has several strengths. To our knowledge, it involves the largest cohort evaluating a loading dose of vancomycin in children, and it also includes one of the most diverse cohorts. We enrolled 39 Native American children (representing 25.8% of the entire cohort), thus capturing a group typically not well described in pediatric pharmacological studies. The study has several

limitations as well. Most notable is its lack of randomization, which may have led to imbalances in potential prognostic factors. Indeed, the mean age of children receiving a loading dose (2018–2019 enrollment) was significantly higher than the mean age of those in the conventional dosing arm (2015 enrollment). However, those subjects excluded from the loading dose cohort for lack of a loading dose were also significantly older than subjects in the control cohort, suggesting that the overall age of subjects receiving vancomycin at our institution may have increased. Between 2015 and 2018, a new antimicrobial stewardship program was instituted, which may have decreased the use of vancomycin in younger subjects. As a result, our results may not be generalizable to younger patients. This is of particular importance given that younger patients may be less likely to achieve target trough concentrations with standard dosing.^{15,40} However, after controlling for age in our regression model, the use of a loading dose was still significantly associated with attainment of an initial target trough concentration. The difference in body weights between the 2 groups was likely related to the aforementioned age differences. Other limitations of this study include the retrospective design (which limited our ability to collect data on variables not captured in the medical record, such as the rationale for not providing a loading dose), a small sample size, and single-center enrollment. We were also unable to analyze outcomes by diagnosis (e.g., MRSA bacteremia), given the small numbers of specific diagnoses in each group. Further investigation of loading doses with prospective randomized controlled trials and larger sample sizes are warranted, as are studies of loading doses correlated to potentially better markers of clinical outcomes (e.g., AUC/MIC) in children.

Conclusions

The use of vancomycin loading doses in hospitalized children may improve the ability to rapidly achieve

target trough concentrations without a corresponding risk of nephrotoxicity. Despite this, however, the majority of subjects receiving vancomycin loading doses still demonstrated subtherapeutic trough concentrations. Additional prospective study is required to assess the effect of loading doses on newer parameters, such as the AUC/MIC, and to further validate and optimize vancomycin loading doses in children of varying ages, racial groups, and in various clinical settings.

ARTICLE INFORMATION

Affiliations School of Medicine (ED), The University of New Mexico (ED), Inpatient Pharmacy Department (RH, ML, KR), The University of New Mexico Hospital, Department of Pediatrics and Division of Infectious Diseases (WD), School of Medicine, The University of New Mexico, Albuquerque, NM

Correspondence Walter Dehority, MD, MSc; wdehority@salud.unm.edu

Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all the data and take responsibility for the integrity and accuracy of the data analysis.

Ethical Approval and Informed Consent The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines on human experimentation and have been approved by the University of New Mexico Institutional Review Board, with a waiver of informed consent granted (IRB 18-166).

Accepted December 29, 2019

Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org

REFERENCES

1. Vancomycin hydrochloride [package insert]. New York, NY: Pfizer; 2010.
2. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. *Clin Infect Dis*. 2006;42(suppl 1):S35–S39.
3. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2009;66(1):82–98.
4. Gordon CL, Thompson C, Carapetis J, et al. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. *Pediatr Infect Dis J*. 2012;31(12):1269–1271.
5. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia. *J Clin Microbiol*. 2004;42(6):2398–2401.
6. Thomsen IP. The concern for vancomycin failure in the treatment of pediatric *Staphylococcus aureus* disease. *Clin Infect Dis*. 2019;68(3):373–374.
7. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. *Pediatr Infect Dis J*. 2013;32:e155–e163.
8. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with *Staphylococcus* species by using a curve stripping program to describe the relationship between concentration and pharmacodynamics response. *Antimicrob Agents Chemother*. 1992;36(8):1766–1769.
9. Löwdin E, Odenholt I, Cars O. In vitro studies of pharmacodynamics properties of vancomycin against *Staphylococcus aureus* and *Staphylococcus epidermidis*. *Antimicrob Agents Chemother*. 1998;42(10):2739–2744.
10. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of *Staphylococcus aureus* under aerobic and anaerobic conditions. *J Antimicrob Chemother*. 1996;38(4):589–597.
11. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with *Staphylococcus aureus* lower respiratory tract infections. *Clin Pharmacokinet*. 2004;43(13):925–942.
12. Neely MN, Kato L, Young G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. *Antimicrob Agent Chemother*. 2018;62(2):1–12.
13. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis*. 2007;44(12):1536–1542.
14. Lexicomp online. Vancomycin. Hudson, OH: 2019. <https://online.lexi.com/lco/action/login>. Accessed June 6, 2019.
15. Orr H, Trone D, Elder J, Raj A. Assessment of initial vancomycin dosing in pediatric oncology patients. *Children*. 2017;4(9):e79–e83.
16. Hsu A, Hamdy R, Huang Y, et al. Association between vancomycin trough concentrations and duration of methicillin-resistant *Staphylococcus aureus* bacteremia in children. *J Pediatr Infect Dis Soc*. 2018;7(4):338–341.
17. Hoang J, Dersch-Mills D, Bresee L, et al. Achieving therapeutic vancomycin levels in pediatric patients. *Can J Hosp Pharm*. 2014;67(6):416–422.
18. Durham SH, Simmons ML, Mulherin DW, Foland JA. An evaluation of vancomycin dosing for complicated infections in pediatric patients. *Hosp Pediatr*. 2015;5(5):276–281.
19. Randolph AG, Xu R, Novak T, et al. Vancomycin monotherapy may be insufficient to treat methicillin-resistant *Staphylococcus aureus* coinfection in children with influenza-related critical illness. *Clin Infect Dis*. 2019;68(3):365–372.
20. Yoo RN, Kim SH, Lee J. Impact of initial vancomycin trough concentration on clinical and microbiological outcomes of methicillin-resistant *Staphylococcus aureus* bacteremia in children. *J Korean Med Sci*. 2017;32(1):22–28.
21. Hamdy RF, Hsu AJ, Stockman C, et al. Epidemiology of methicillin-resistant *Staphylococcus aureus* bacteremia in children. *Pediatrics*. 2017;139(6):e20170183.

22. Reardon J, Lau TT, Ensom MH. Vancomycin loading doses: a systematic review. *Ann Pharmacother*. 2015;49(5):557–565.
23. Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardized loading dose results in earlier therapeutic levels. *Intern Med J*. 2012;42(1):23–29.
24. Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. *J Antimicrob Chemother*. 2001;47(2):246. doi:10.1093/jac/47.2.246
25. Demirjian A, Finkelstein Y, Nava-Ocampo A, et al. A randomized controlled trial of a vancomycin loading dose in children. *Pediatr Infect Dis J*. 2013;32(11):1217–1223.
26. Bhagat PH, Bartlett AH. Evaluation of vancomycin loading dose in pediatric patients. *Open Forum Infect Dis*. 2014;1(suppl 1):S149–S150.
27. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology—drug disposition, action, and therapy in infants and children. *New Engl J Med*. 2003;349(12):1157–1167.
28. Andreoli SP. Acute kidney injury in children. *Pediatr Nephrol*. 2009;24(2):253–263.
29. Whyte DA, Fine RN. Acute renal failure in children. *Pediatr Rev*. 2008;29(9):299–310.
30. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society. *Neurourol Urodyn*. 2016;35(4):471–481.
31. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52(3):e18–e56.
32. Regen RB, Schuman SS, Chhim RF, et al. Vancomycin treatment failure in children with methicillin-resistant *Staphylococcus aureus* bacteremia. *J Pediatr Pharmacol Ther*. 2019;24(4):312–319.
33. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377–381.
34. Downes KJ, Cowden C, Laskin B, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. *JAMA Pediatr*. 2017;171(12):e173219. doi:10.1001/jamapediatrics.2017.3219
35. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. *J Pediatr*. 2011;158(3):422–426.
36. Matson KL, Shaffer CL, Beck GL, et al. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study. *Pharmacotherapy*. 2015;35(3):337–343.
37. Chang CN, Lo WT, Chan MC, Wang CC. A retrospective study to estimate serum vancomycin trough concentrations in pediatric patients with current recommended dosing regimen. *J Med Sci*. 2018;38(6):275–279.
38. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant *Staphylococcal* infections. *Pediatr Infect Dis J*. 2013;32(10):1077–1079.
39. Gwee A, Cranswick N, McMullan B, et al. Continuous versus intermittent vancomycin infusions in infants: a randomized controlled trial. *Pediatrics*. 2019;143(2):e20182179. doi:10.1542/peds.2018-2179
40. Hurst AL, Baumgartner C, MacBrayne CE, Child J. Experience with continuous infusion vancomycin dosing in a large pediatric hospital. *J Pediatr Infect Dis Soc*. 2019;8(2):174–179.
41. Cataldo MA, Toacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. *J Antimicrob Chemother*. 2012;67(1):17–24.
42. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. *J Clin Pharm Ther*. 2004;29(4):351–357.
43. Arrieta AC, Bradley JS, Popejoy MW, et al. Randomized multicenter study comparing safety and efficacy of daptomycin versus standard-of-care in pediatric patients with staphylococcal bacteremia. *Pediatr Infect Dis J*. 2018;37(9):893–900.
44. Korczowski B, Antadze T, Giorgobiania M, et al. A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection. *Pediatr Infect Dis J*. 2016;35(8):e239–e247.
45. Blumer JL, Ghonghadze T, Cannavino C, et al. A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia. *Pediatr Infect Dis J*. 2016;35(7):760–766.
46. Gonzalez D, Bradley JS, Blumer J, et al. Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age. *Pediatr Infect Dis J*. 2017;36(7):645–653.